Table 2.
Coronary Heart Disease, Stroke, and Venous Thromboembolism Odds Ratio Estimates for Postmenopausal Hormone Therapy versus Placebo according to Number of Minor Alleles of Estrogen Receptor SNPs
| Polymorphism | Odds ratio estimate (95% confidence interval)1 | Marginal p2 | Corrected p3 | ||
|---|---|---|---|---|---|
| Number of minor SNP alleles | |||||
| 0 | 1 | 2 | |||
| Coronary heart disease | |||||
| ESR1 IVS1-401 | 2.06(1.06,4.01) | 0.92(0.59,1.42) | 1.28(0.63,2.58) | 0.300 | 0.993 |
| ESR1 Exon 1+30 | 1.64(0.87,3.07) | 0.96(0.61,1.53) | 1.24(0.63,2.43) | 0.511 | 1.0000 |
| ESR1 IVS1-354 | 1.60(0.97,2.64) | 0.90(0.56,1.45) | 1.20(0.46,3.16) | 0.261 | 0.917 |
| ESR1 IVS1-1415 | 1.26(0.79,2.02) | 1.15(0.70,1.87) | 1.16(0.41,3.31) | 0.825 | 1.000 |
| ESR1 IVS1-1505 | 1.95(1.02,3.72) | 0.94(0.60,1.46) | 1.18(0.58,2.41) | 0.262 | 0.979 |
| ESR1 IVS1-1989 | 1.19(0.81,1.74) | 1.01(0.52,1.96) | 3.40(0.42,27.3) | 0.826 | 1.000 |
| ESR2 1730 | 1.52(0.89,2.59) | 1.12(0.71,1.77) | 0.91(0.37,2.22) | 0.273 | 0.999 |
| Stroke | |||||
| ESR1 IVS1-401 | 1.62(0.86,3.05) | 0.82(0.49,1.38) | 2.89(1.21,6.89) | 0.541 | 1.000 |
| ESR1 Exon 1+30 | 1.49(0.79,2.80) | 1.01(0.60,1.69) | 2.36(1.00,5.56) | 0.563 | 1.000 |
| ESR1 IVS1-354 | 1.72(1.01,2.95) | 0.84(0.49,1.43) | 3.00(0.84,10.7) | 0.680 | 1.000 |
| ESR1 IVS1-1415 | 1.60(0.97,2.64) | 0.94(0.54,1.65) | 2.13(0.54,8.33) | 0.602 | 1.000 |
| ESR1 IVS1-1505 | 1.48(0.79,2.76) | 0.86(0.51,1.45) | 3.31(1.34,8.15) | 0.335 | 0.995 |
| ESR1 IVS1-1989 | 1.12(0.74,1.70) | 1.66(0.74,3.76) | 5.95(0.71,49.9) | 0.107 | 0.835 |
| ESR2 1730 | 2.20(1.25,3.87) | 0.99(0.59,1.67) | 0.71(0.26,1.97) | 0.019 | 0.103 |
| Venous thrombo-embolism | |||||
| ESR1 IVS1-401 | 2.97(1.43,6.14) | 2.08(1.22,3.54) | 1.75(0.77,3.95) | 0.330 | 1.000 |
| ESR1 Exon 1+30 | 2.74(1.33,5.68) | 2.24(1.28,3.91) | 1.65(0.78,3.46) | 0.330 | 1.000 |
| ESR1 IVS1-354 | 4.09(2.23,7.52) | 1.27(0.74,2.19) | 2.06(0.62,6.86) | 0.033 | 0.661 |
| ESR1 IVS1-1415 | 3.03(1.75,5.26) | 1.60(0.90,2.83) | 1.64(0.42,6.42) | 0.143 | 0.930 |
| ESR1 IVS1-1505 | 3.18(1.55,6.53) | 1.95(1.14,3.34) | 1.68(0.74,3.85) | 0.229 | 1.000 |
| ESR1 IVS1-1989 | 2.11(1.34,3.34) | 2.40(1.04,5.55) | 5.79(0.48,69.8) | 0.684 | 1.000 |
| ESR2 1730 | 3.67(1.83,7.39) | 1.73(1.04,2.88) | 1.91(0.62,5.85) | 0.160 | 0.693 |
Obtained from a logistic regression model adjusted for hysterectomy status, age, race/ethnicity, body mass index, waist/hip ratio, treated diabetes, smoking status, alcohol use, physical activity, history of cardiovascular disease, left ventricular hypertrophy on electrocardiogram, systolic blood pressure, history of hypertension, aspirin use, statin use, history of high cholesterol requiring pills, and hormone use at baseline.
One degree of freedom test of no interaction between treatment assignment (active vs placebo) and polymorphism linear in the number of minor SNP alleles, adjusted for covariates as above.
Multiple comparison permutation adjusted p-values, based on 1,000 permutations. The SNP by treatment interaction was permuted at each iteration.